4 Matching Annotations
  1. Dec 2021
  2. Aug 2021
    1. Periodic Limb Movements of Sleep measurementsconfirmedthat ULDNallowed equivalent control of limb movements at half the prior dose of D2/3 agonists. Although the naltrexone dosewas 0.15 ug, the effect was retained at 100 ug and 1 mg(Bear and Kessler, 2014a,2014b).Thus, naltrexone proved effective forRLS, putativelyby facilitating sensitization of D2/3 agonists.

      The sources are patents. 2014a and 2014b.

      It is interesting that the benefits were retained over a large dose range. Oddly, full LDN doses (when combined with benzos) can help treat tardive dyskinesia. Thus, it seems plausible that the benefits for RLS are retained at even higher doses. I've not yet checked the sources to see if higher doses were tested. That is, doses over 1 mg. I doubt they were, because it would probably have been mentioned here.

  3. Jan 2019
    1. naltrexone in their drinking water (5 mg/L)

      Based on water intake of 10ml per 100g body mass, that should translate to 0.5 mg/kg. This is one of the few studies using LDN as opposed to ULDN.

    1. Treatment effects were more pronounced at discharge

      Symptoms in the treatment group continually improved, whereas symptoms in the placebo group plateaued. Thus, I'm interested in seeing a longer treatment period. Projecting from symptom scores, elimination of symptoms would occur in about 10 days.